g260361mmi021.gif
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
Big medical bet: Why this Philly area pharma company's shares jumped 65 percent in a week
/arc-anglerfish-arc2-prod-pmn.s3.amazonaws.com/public/YST6UFBNEVBAXNOUKDYSHHF4AM.PNG "Synthetic CBD from Main Line biotech gets fast track status from FDA")
Synthetic CBD from Main Line biotech gets fast track status from FDA
Zynerba Pharmaceuticals Inc receives guidance from the US Food and Drug Administration on a confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome
Should You Buy Zynerba Pharmaceuticals Inc (ZYNE) Stock on Thursday?
Zynerba Pharmaceuticals Inc's CBD skin gel Zygel offers a potential goldmine of therapies for Fragile X syndrome, and other conditions
Zynerba Pharmaceuticals Presents During NFXF's 2022 Industry Updates | NFXF
Zynerba Pharmaceuticals Presents During NFXF's 2022 Industry Updates | NFXF
Shares of Devon-Based Zynerba Pharmaceuticals Surge After Firm Wins Patent
g260361mmi008.gif
Zynerba Pharmaceuticals, Inc. General Corporate Statement (Form8) - Zynerba Pharmaceuticals (NASDAQ:ZYNE) - Benzinga
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™
Zynerba Pharmaceuticals Inc updates on its meeting with the US Food and Drug Administration regarding its Fragile X syndrome program using Zygel
zynerba-pipeline-10-16 - Zynerba
BRAIN Industry Spotlight: Zynerba Pharmaceuticals
Zynerba: Transdermal Cannabinoids Have Significant Potential (NASDAQ:ZYNE) | Seeking Alpha
Zygel - Zynerba
EDGAR Filing Documents for 0001104659-22-128854
Zynerba Pharma Receives FDA Guidance For Phase 3 Trial Of Zygel; Street Sees 75% Upside
